Allspring Global Investments Holdings LLC Has $10.55 Million Stock Holdings in LivaNova PLC $LIVN

Allspring Global Investments Holdings LLC cut its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 18.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 234,311 shares of the company’s stock after selling 54,004 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.43% of LivaNova worth $10,549,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. GAMMA Investing LLC raised its position in shares of LivaNova by 182.5% during the second quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock worth $28,000 after purchasing an additional 407 shares during the period. CWM LLC raised its position in shares of LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company’s stock worth $34,000 after purchasing an additional 299 shares during the period. Parallel Advisors LLC raised its position in shares of LivaNova by 1,312.3% during the second quarter. Parallel Advisors LLC now owns 1,031 shares of the company’s stock worth $46,000 after purchasing an additional 958 shares during the period. Caitong International Asset Management Co. Ltd raised its position in shares of LivaNova by 415.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company’s stock worth $58,000 after purchasing an additional 1,184 shares during the period. Finally, Strs Ohio acquired a new stake in shares of LivaNova during the first quarter worth $130,000. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Stock Performance

LIVN opened at $53.73 on Friday. The company has a market cap of $2.93 billion, a PE ratio of -13.81 and a beta of 0.95. The stock has a 50-day moving average of $54.30 and a 200-day moving average of $46.37. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $58.91. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.21. The company had revenue of $352.50 million during the quarter, compared to the consensus estimate of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The firm’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.93 EPS. As a group, equities research analysts forecast that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LIVN. Barclays boosted their target price on LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 21st. Needham & Company LLC reissued a “buy” rating and set a $64.00 price target on shares of LivaNova in a research report on Wednesday, September 3rd. The Goldman Sachs Group set a $55.00 price target on LivaNova and gave the company a “neutral” rating in a research report on Wednesday, October 1st. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of LivaNova in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $59.71.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.